Accuray (ARAY) vs NeuroOne Medical Technologies (NMTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Accuray (ARAY) has outperformed NeuroOne Medical Technologies (NMTC) over the past year, gaining 97.6% versus a loss of 82.9%. Over five years, ARAY leads with a -59.5% price change compared with -95.2% for NMTC. Accuray is the larger company by market cap ($6.2 million vs $5.9 million), about 1.0 times the size, while NeuroOne Medical Technologies is growing revenue faster (+163.5% vs -12.3%).
Accuray converts more of its revenue into profit, with a net margin of -12.2% versus -39.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARAY | NMTC |
|---|---|---|
| Share price | $2.08 | $0.6521 |
| Market cap | $6.22M | $5.94M |
| 1-day change | -2.12% | -3.38% |
| YTD return | +153.05% | -85.66% |
| 1-year return | +97.62% | -82.91% |
| 5-year return | -59.47% | -95.19% |
| EPS (TTM) | $-5.60 | $-0.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $401.95M | $9.10M |
| Revenue growth (YoY) | -12.34% | +163.47% |
| Net income (latest FY) | $-49.19M | $-3.61M |
| Gross margin | 27.73% | 56.51% |
| Operating margin | -6.58% | -46.46% |
| Net margin | -12.24% | -39.63% |
| 52-week high | $45.20 | $6.12 |
| 52-week low | $2.05 | $0.61 |
| Distance from 52-week high | -95.41% | -89.34% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | — | +1014.86% |
| Average volume | 201.35K | 337.67K |
| Shares outstanding | 3.00M | 9.11M |
| Employees | 809 | 18 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARAY has outperformed NMTC by 180.5 percentage points over the past year.
- Accuray is more profitable, keeping -12.2 cents of every revenue dollar as net income versus -39.6 cents for NeuroOne Medical Technologies.
- NeuroOne Medical Technologies grew revenue faster in its latest fiscal year (+163.47% vs -12.34%).
About Accuray
ARAY stock →Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
Health Care · Medical/Dental Instruments · 809 employees
About NeuroOne Medical Technologies
NMTC stock →NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders.
Health Care · Medical/Dental Instruments · 18 employees
ARAY vs NMTC FAQ
Which is bigger, Accuray or NeuroOne Medical Technologies?
Accuray (ARAY) is larger, with a market capitalization of $6.22M compared with $5.94M for NeuroOne Medical Technologies (NMTC).
Which stock has performed better over the past year, ARAY or NMTC?
ARAY returned +97.62% over the past 12 months, compared with -82.91% for NMTC (price return, excluding dividends). Past performance does not predict future results.
Are Accuray and NeuroOne Medical Technologies in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.